Figure 1 | Scientific Reports

Figure 1

From: Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis

Figure 1

Serum anti-RBD IgG in participants with RA and controls following SARS-CoV-2 vaccination. (a) Anti-RBD IgG in the serum was measured by ELISA for participants with RA (open circles), and controls (C, grey squares). The solid line represents the median. PreX is pre dose X, 2–6wksX is 2–6 weeks post dose X, 3moX is 3 months post dose X. (b) Multivariable linear mixed model estimates (Log-twofold changes ± SD) comparing RA and C cohorts, and the effects of different parameters on anti-RBD IgG levels. (c) Multivariable linear mixed model estimates (Log-2-fold changes ± SD) within the RA cohort of the effects of different parameters, including immunomodulatory drugs, on anti-RBD IgG levels following SARS-CoV-2 vaccination. Costim denotes costimulation. (d) Anti-RBD IgG levels in participants with RA on costimulation inhibitors, JAK inhibitors, TNF inhibitors, other drug classes (steroids ± DMARDs), and controls (C, grey squares) at 2–6 weeks post dose 3.

Back to article page